摘要
克罗恩病(CD)和溃疡性结肠炎(UC)是两种特发性肠道炎性疾病。此文对新出现的生物制剂之一,英夫利昔单抗(infliximab)在这类疾病中实际应用方面的依据进行评论和回顾,包括剂量、疗效、注意事项和不良反应,并作一总结。
Crohn's disease and ulcerative colitis are two idiopathic intestinal inflammatory diseases, This article comments and reviews on the infliximab which is one of the new biologic agents, includes dosage,curative effect,caution and toxicity.
出处
《国际消化病杂志》
CAS
2008年第4期273-276,共4页
International Journal of Digestive Diseases